Number of pages: 100 | Report Format: PDF | Published date: January 27, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global thrombosis associated with cancer market is expected to register a revenue CAGR of 8.9% during the forecast period from 2022 to 2030.
Thrombosis Associated with Cancer Market Fundamentals
Cancer thromboembolism can range from arterial or venous thromboembolism (VTE) to disseminated intravascular coagulation. Despite the well-known link between cancer and thromboembolic disorder, the processes promoting thromboembolic events in cancer patients are not completely understood and appear complex. Cancer patients are commonly hypercoagulable or prothrombotic, as they have abnormalities in all three components of Virchow's triad, which contribute to thrombosis. Furthermore, cancer cells can trigger the coagulation cascade and other prothrombotic features of host cells. Thrombotic complications in cancer can vary from arterial or VTE to disseminated intravascular coagulation. Low‐molecular‐weight heparin (LMWH), compared to warfarin, has been shown to reduce the risk of recurrent VTE in patients with thrombosis associated with cancer and is, therefore, the standard treatment for acute thrombosis associated with cancer for the past 15 years.
Trousseau's syndrome (cancer-associated thrombosis) is the second largest cause of death among cancer patients following cancer death. Patients with cancer have a 4- to 7-fold increased risk of VTE compared to individuals who do not have cancer. The causes of this poor coagulation are associated with general patient-related risk factors as well as cancer-specific or treatment-specific variables. Furthermore, cancer-related thrombosis is clinically presented as deep vein thrombosis (DVT), pulmonary embolism (PE), chronic DIC linked with NBTE, and arterial thrombosis. Secondary thrombotic episodes associated with chemotherapy or central venous catheterization are sometimes described as cancer-associated thrombosis. As a result, the incidence of cancer-related thrombosis varies greatly between studies, depending on the patient population.
Thrombosis Associated with Cancer Market Dynamics
Cancer is associated with an increased incidence of VTE (4% to 20%) and arterial thrombosis (2% to 5%). VTE is the second largest cause of death in the cancer community, closely behind cancer itself. Cancer patients have a 4- to 7-fold increased risk of VTE and a 2-fold increased risk of significant hemorrhage on anticoagulation compared to individuals without cancer. Cancer patients’ quality of life may be impacted by VTE and its treatment, which can also have other negative effects, such as bleeding or recurring VTE. Consequently, the most effective VTE prevention and therapy are essential elements of patient care in this population. Furthermore, the growing global oncology burden caused by increased alcohol and tobacco consumption is propelling the global thrombosis associated with cancer market revenue growth. In its report GLOBOCAN, the International Agency for Research on Cancer (IARC) stated that around 19.3 million new cancer cases and nearly 10 million cancer-related deaths were registered globally in 2020. According to the IARC, new cancer cases are anticipated to climb by 47% globally between 2020 and 2040. This factor is expected to drive revenue growth opportunities in the market during the forecast period.
Thrombosis Associated with Cancer Market Ecosystem
The global thrombosis associated with cancer market has been analyzed from three perspectives: drug class, indication, and region.
Thrombosis Associated with Cancer Market by Drug Class
Based on the drug class, the global thrombosis associated with cancer market is segmented into heparin, vitamin K antagonist, factor Xa inhibitors, and direct thrombin inhibitors.
The heparin segment is sub-segmented into low molecular weight heparin (LMWH) and unfractionated heparin (UFH).
The heparin segment dominates the global market owing to its potent anticoagulant effect. Heparin is used to prevent and treat VTE in cancer patients. Anticoagulant therapy with heparin helps to improve prognosis and survival in individuals with diversiform tumors, according to clinical research. Heparin is a complex mixture of naturally occurring GAG extracted from pig intestines that is typically produced as a sodium salt. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are the two forms of heparin, with the latter comprising several subtypes such as enoxaparin, nadroparin calcium, dalteparin sodium, and tinzaparin. Many different forms of heparin have been synthesized as a result of the advancement of current biosynthetic processes, with certain heparin chemical groups being added or replaced.
Thrombosis Associated with Cancer Market by Indication
Based on the indication, the global thrombosis associated with cancer market is segmented into venous thromboembolism and arterial thrombosis.
The venous thromboembolism segment is expected to dominate the market during the forecast period. VTE, the most common clinical manifestation of cancer-related thrombosis, encompasses both DVT and PE and affects 4-20% of cancer patients. In contrast, 20% of individuals with symptomatic DVT had active cancer.
Thrombosis Associated with Cancer Market by Region
Based on the region, the global thrombosis associated with cancer market is segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America dominates the global market in terms of revenue share. The growth of the market is characterized by rising disease prevalence and the need for treatment, together with increasing disease diagnosis and the adoption of cutting-edge therapies in the region. Moreover, increased healthcare expenditures, rise in the inclination of the regional population toward adoption of novel treatment alternatives, and presence of key players with their pipeline candidates and planned launches are projected to drive the North America market during the forecast period.
Europe is expected to be the most opportunistic market during the forecast period. This is due to increasing technological advancements in the diagnosis of various types of cancers. Furthermore, rising prevalence of cancer and increasing number of cancer fatalities are likely to fuel the expansion of the Europe thrombosis associated with cancer market in the coming years.
Thrombosis Associated with Cancer Market Competitive Landscape
Some of the prominent players operating in the global thrombosis associated with cancer market include:
Thrombosis Associated with Cancer Market Strategic Development/s
Europe is the key growth region in the global thrombosis associated with cancer market.
Rising incidence of cancer, increase in initiatives by governments and other organizations to spread disease awareness, and technological advancements in developed countries are expected to propel the global market revenue growth.
GSK plc., Janssen Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited., Bristol-Myers Squibb Co., and Sanofi-Aventis U.S. LLC are among the prominent players operating in the market.
The venous thromboembolism segment dominates the global thrombosis associated with cancer market.
Cancer thromboembolism can range from arterial or VTE to disseminated intravascular coagulation. Despite the well-known link between cancer and thromboembolic disorder, the processes that promote thromboembolic events in cancer patients are not completely understood and appear to be complex. Cancer patients are commonly hypercoagulable or prothrombotic, as they have abnormalities in all three components of Virchow's triad, contributing to thrombosis.
*Insights on financial performance are subject to availability of the information in the public domain